BioNTech Cancer Therapy Misses Main Goal in Head and Neck Trial
BioNTech said its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer. Its U.S.-listed shares were down nearly 6% in premarket trading.
BioNTech said on Tuesday that its experimental mRNA cancer immunotherapy did not achieve the trial’s first primary goal. The mid-to-late-stage study involved patients with head and neck cancer. , fell nearly 6% in premarket trading.